| Not Yet Recruiting | LAmbre™ II Left Atrial Appendage Occluder and Occluder Delivery System for Patients With Non-Valvular Atrial F NCT07455539 | Prince of Wales Hospital, Shatin, Hong Kong | N/A |
| Not Yet Recruiting | Applause Study I - Append System Early Feasibility Study NCT07278869 | Append Medical Ltd. | N/A |
| Enrolling By Invitation | Apixaban Versus Rivaroxaban in Non Valvular Atrial Fibrillation NCT06862726 | Les Laboratoires des Médicaments Stériles | Phase 4 |
| Recruiting | Stroke Risk Assessment and Markers of Blood Clotting in Patients With Newly Diagnosed Non-valvular Atrial Fibr NCT06949319 | Nedim Tojaga | — |
| Suspended | A Pivotal Investigational Device Exemption Study on Laminar Left Atrial Appendage Elimination NCT06168942 | Biosense Webster, Inc. | N/A |
| Terminated | Amplatzer Amulet China Post Market Study (PMS) NCT06189365 | Abbott Medical Devices | — |
| Unknown | Exploratory Observation of Two Short-term Regimens After LAA Occlusion by LAMax LAAC® Device for Subjects With NCT05761704 | Second Affiliated Hospital, School of Medicine, Zhejiang University | N/A |
| Active Not Recruiting | An Early Feasibility Study Evaluating the Safety and Efficacy of the Laminar Left Atrial Appendage Closure Sys NCT05565599 | Biosense Webster, Inc. | N/A |
| Completed | Safety and Effectiveness of Apixaban Compared to Warfarin in Patients With Non-valvular Atrial Fibrillation (a NCT05471505 | Pfizer | — |
| Completed | Safety and Effectiveness of Apixaban in Very Elderly Patients With Non-valvular Atrial Fibrillation (NVAF) Com NCT05438888 | Pfizer | — |
| Completed | Safety and Effectiveness of Apixaban Compared to Warfarin in Secondary Prevention in Patients With Atrial Fibr NCT05321810 | Pfizer | — |
| Completed | Population Pharmacokinetics of Edoxaban in Chinese Patients With Non-Valvular Atrial Fibrillation NCT05320627 | China National Center for Cardiovascular Diseases | Phase 4 |
| Completed | A Study to Collect Information on the Characteristics of Elderly Belgian Patients With NVAF That Are Treated W NCT04722679 | Bayer | — |
| Completed | Real-world Study on Edoxaban Treatment for Patients With Non-valvular Atrial Fibrillation in China NCT04747496 | Daiichi Sankyo | — |
| Recruiting | Study of the Effects of Anticoagulant Interruption Covered by Percutaneous Left Atrial Occlusion in Patients W NCT04701749 | University Hospital, Clermont-Ferrand | — |
| Active Not Recruiting | Evaluation of Safety and Performance of the Omega™ LAA (Left Atrial Appendage) Occluder and Omega™ Delivery Sy NCT04829929 | Eclipse Medical Ltd. | N/A |
| Recruiting | Left Atrial Appendage Closure as Secondary Prevention of Atrial Fibrillation-related Embolic Events NCT04559243 | Lifetech Scientific (Shenzhen) Co., Ltd. | — |
| Completed | Edoxaban in Patients With Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention NCT04519944 | Daiichi Sankyo | — |
| Completed | Observe the Safety and Effectiveness of the WATCHMAN FLX™ for Subjects in Hong Kong NCT04096963 | Boston Scientific Corporation | — |
| Completed | Study to Gather Information on the Kidney Function of Patients With Non-valvular Atrial Fibrillation (Irregula NCT04297072 | Bayer | — |
| Completed | Study Aims to Collect Information in Routine Clinical Practice in Italy About the Number of Patients Suffering NCT04174859 | Bayer | — |
| Completed | The Conformal Prague Study NCT04193826 | Conformal Medical, Inc | N/A |
| Completed | Watchman FLX Left Atrial Appendage Closure Device Post Approval Study ( Europe Only) NCT02654470 | Boston Scientific Corporation | — |
| Completed | LAMax Vs. Watchman LAAC Device for Subjects With Non-valvular AF to Reduce the Risk of Stroke NCT04429646 | Second Affiliated Hospital, School of Medicine, Zhejiang University | N/A |
| Unknown | Registry to Evaluate Chinese Real-World Clinical Outcomes in Patients With AF Using the WATCHMAN Left Atrial A NCT03917563 | Xijing Hospital | N/A |
| Active Not Recruiting | The CONFORMAL Early Feasibility Study NCT03616028 | Conformal Medical, Inc | N/A |
| Terminated | A Nationwide Observational Study Looking at Effectiveness and Bleeding Complications of NOACs vs. VKA in Non-v NCT03715725 | Bayer | — |
| Completed | Safety and Effectiveness of Oral Anticoagulants in Patients With Non-valvular Atrial Fibrillation NCT03570047 | Pfizer | — |
| Completed | Rivaroxaban in Patients With Atrial Fibrillation Undergoing PCI NCT03315650 | IHF GmbH - Institut für Herzinfarktforschung | — |
| Withdrawn | Study to Describe Risk of Bleeding in Patients Depending on the Different Anticoagulant Therapy They Are on fo NCT03508258 | Bristol-Myers Squibb | — |
| Completed | Better Outcomes for Anticoagulation Treatment Through Observation of Atrial Rhythm NCT03515083 | Saint Luke's Health System | N/A |
| Terminated | WAVECREST Post Market Clinical Follow-Up (PMCF) Study NCT03204695 | Coherex Medical | N/A |
| Unknown | A Pilot Study of Edoxaban in Patients With Non-Valvular Atrial Fibrillation and Left Atrial Appendage Closure NCT03088072 | Scripps Health | Phase 4 |
| Unknown | Canadian Left Atrial Appendage Closure Study NCT03133806 | Cardia Inc. | N/A |
| Unknown | Study of Safety and Efficacy of a Left Atrial Appendage Occulder NCT02937025 | Ya-Wei Xu | Phase 1 / Phase 2 |
| Terminated | Evolution of Coagulation Activity in Non Valvular Atrial Fibrillation Patients Under Apixaban NCT03136510 | Hopital Lariboisière | N/A |
| Completed | Clinical and Economic Outcomes of Oral Anticoagulants in Non-valvular Atrial Fibrillation NCT03087487 | Bristol-Myers Squibb | — |
| Withdrawn | Bleeding Events and Oral Anticoagulant Treatment in Non-Valvular Atrial Fibrillation NCT03002740 | Bristol-Myers Squibb | — |
| Completed | Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Co NCT02502396 | M.D. Anderson Cancer Center | — |
| Completed | Antithrombotic Strategy Variability In ATrial Fibrillation and Obstructive Coronary Disease Revascularized Wit NCT02362659 | Icahn School of Medicine at Mount Sinai | — |
| Unknown | Therapy With New Oral Anticoagulants NCT02222090 | Sheba Medical Center | — |
| Completed | Real Evidence of Anticoagulation Treatment in Non-valvular Atrial Fibrillation in Germany, UK and France: REAC NCT02488421 | Bristol-Myers Squibb | — |
| Completed | Better Adherence With New Oral Anticoagulant in Atrial Fibrillation : Effectiveness of a Personalized Educatio NCT02422602 | University Hospital, Montpellier | N/A |
| Completed | Assessment of an Education and Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (A NCT01884350 | Bristol-Myers Squibb | Phase 4 |
| Completed | Local Adaptation of Cost Effectiveness Model for Apixaban Atrial Fibrillation Indication - Venezuela NCT02756481 | Bristol-Myers Squibb | — |
| Unknown | Evaluation of Effectiveness and Safety of Xa Inhibitor for the Prevention of Stroke And Systemic Embolism in a NCT02147444 | Tohoku University | — |
| Completed | Safety and Pharmacokinetics Study of DU-176b Administered to Non-valvular Atrial Fibrillation With Severe Rena NCT01857622 | Daiichi Sankyo Co., Ltd. | Phase 3 |